I-Inside Scoop mayelana Nezindleko Zokwelashwa Umdlavuza Webele eNdiya - Isambulo Okufanele Sifundwe!

Breast cancer accounts for 31% of all cancers diagnosed in Indian women, making it the leading type of cancer. This serious disease must be treated at an early stage for the best outcomes. Our blog breaks down the breast cancer t..

Abemaciclib, i-aromatase inhibitor, U-Eli Lilly neNkampani, ukwelashwa kwe-endocrine, Tamoxifen, UVerzenio

I-Abemaciclib ngokwelashwa kwe-endocrine kuvunywe yi-FDA kumdlavuza webele we-HER 2 omuhle

Mashi 2023: I-Abemaciclib (Verzenio, Eli Lilly and Company) kanye nokwelashwa kwe-endocrine (tamoxifen noma i-aromatase inhibitor) kugunyazwe i-Food and Drug Administration (FDA) ukuze kusetshenziswe i-adjuvant yeziguli ezikhulile ezine-.

China, I-Enhertu, HER 2 positive

I-Enhertu igunyazwe e-China ezigulini ezinomdlavuza webele we-HER2-positive metastatic

Feb 2023: Enhertu (trastuzumab deruxtecan) from AstraZeneca and Daiichi Sankyo has been approved as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ..

Hamsa, Hamsa Nandini, UMirchi, Ifilimu kaMirchi

Umlingisi u-Hamsa Nandini Uhlinzeka Ngesibuyekezo Ngonyaka Owodwa Ngemva Kokwelashwa Umdlavuza Webele

Feb 2023: U-Hamsa Nandini, owatholakala ene-Grade III Invasive Carcinoma (Umdlavuza Webele) ngo-2021, ubuyekeze abalandeli bakhe be-Instagram ngesimo sakhe sezempilo. Lo mlingisi oseke wabonakala kumafilimu eTelugu afana noMirchi noLege.

I-Sciences yaseGileyadi, sacituzumab govitecan-hziy, I-Trodelvy, I-TROPiCS-02

I-Sacituzumab govitecan-hziy igunyazwe yi-FDA ngomdlavuza webele we-HR-positive

Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cance..

i-elacestrant, I-Orserdu, I-Stemline Therapeutics

I-Elacestrant igunyazwe yi-FDA ngomdlavuza webele we-ER-positive, HER2-negative, ESR1 oguquliwe othuthukisiwe noma we-metastatic

In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced or metastatic breast cancer and are ER-positive, HER2-negative, and h..

Daiichi Sankyo, I-Enhertu, fam-trastuzumab deruxtecan-nxki

I-Fam-trastuzumab deruxtecan-nxki igunyazwe yi-FDA ngomdlavuza webele

Ngo-Ephreli 2022: Iziguli zabantu abadala ezinomdlavuza webele we-HER2 ongenakunqandeka noma one-metastatic ezithole uhlobo lwangaphambili olusekelwe ku-HER2 olusekelwe kuhlelo lwe-metastatic, noma ku-neoadjuvant noma i-adjuvant setting futhi luye lwakhula.

I-AstraZeneca Pharmaceuticals, I-BRCA, gBRCAm, I-Lynparza, i-olaparib, I-OlympiA

I-Olaparib igunyazelwe ukwelashwa kwe-adjuvant yomdlavuza webele wangaphambi kwesikhathi osengozini enkulu

Mashi 2022: I-Food and Drug Administration igunyaze i-olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) yokwelapha i-adjuvant yeziguli ezikhulile ezinegciwane elisusayo noma elisolwa ngokususa i-BRCA-mutated (gBRCAm) h.

Abemaciclib, Okuhle, Dako Omnis, U-Eli Lilly neNkampani, ukwelashwa kwe-endocrine, Tamoxifen, UVerzenio

I-Abemaciclib igunyazwe yi-FDA ngokwelashwa kwe-endocrine komdlavuza webele wakuqala

Okthoba 2021: Ukuphathwa Kwezokudla Nezidakamizwa kugunyaze i-abemaciclib (i-Verzenio, i-Eli Lilly neNkampani) ngokuhlanganiswa nokwelashwa kwe-endocrine (tamoxifen noma i-aromatase inhibitor) yokwelashwa kwe-adjuvant yeziguli zabantu abadala ezine-ho..

KEYTRUDA, Merck, I-Pembrolizumab, I-TNBC

I-Pembrolizumab ivunyelwe yi-FDA ngomdlavuza webele onobungozi obuphakeme besigaba sokuqala

Agasti 2021: IPembrolizumab (Keytruda, Merck) yamukelwa yi-FDA ngomdlavuza webele onobungozi obukhulu, wesigaba sokuqala (i-TNBC) njengokwelashwa kwe-neoadjuvant kuhlangene ne-chemotherapy, futhi kamuva njenge-ejenti eyodwa njenge-adjuv ..